Phase 2 Eczema Trial, Recruiting (NCT07105488)

Phase 2 Eczema Trial, Recruiting NCT07105488 Sponsor: Bluefin Biomedicine, Inc. Condition: Eczema

Printed from Voxsanity (voxsanity.com.au) — NCT07105488 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Eczema

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You are between 18 and 75 years old and have been diagnosed with atopic dermatitis (eczema) for at least one year
Your eczema is moderate to severe and has not been well controlled by creams or ointments applied to the skin
You are willing to follow the study's instructions, attend regular check-up appointments, and avoid certain other medicines during the study

Who may not be able to join:

You currently have certain infections or other conditions that affect your immune system (confirm with trial site)
You have recently taken certain medications that could affect how the study works (confirm with trial site)
You are currently pregnant or breastfeeding

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 27 July 2026

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +1-214-728-6505

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07105488

Sponsor: Bluefin Biomedicine, Inc.

Phase: Phase 2

Status: Recruiting

Condition: Eczema

Trial contact: +1-214-728-6505

More information: https://clinicaltrials.gov/study/NCT07105488

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You are between 18 and 75 years old and have been diagnosed with atopic dermatitis (eczema) for at least one year
Your eczema is moderate to severe and has not been well controlled by creams or ointments applied to the skin
You are willing to follow the study's instructions, attend regular check-up appointments, and avoid certain other medicines during the study

Who may not be able to join:

You currently have certain infections or other conditions that affect your immune system (confirm with trial site)
You have recently taken certain medications that could affect how the study works (confirm with trial site)
You are currently pregnant or breastfeeding

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 27 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 2

Sponsor

Bluefin Biomedicine, Inc.

Registry

ClinicalTrials.gov

Start date

15 July 2025

Est. completion

28 February 2027

Where this trial is recruiting

🇧🇬 Bulgaria 🇨🇦 Canada 🇨🇿 Czechia 🇩🇪 Germany 🇵🇱 Poland 🇪🇸 Spain 🇺🇸 United States

Primary endpoints

Efficacy of BFB759 in AD

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov